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Abstract
Background: The sudden emergence of novel influenza viruses is a global public health concern. Conventional influenza
vaccines targeting the highly variable surface glycoproteins hemagglutinin and neuraminidase must antigenically match the
emerging strain to be effective. In contrast, ‘‘universal’’ vaccines targeting conserved viral components could be used
regardless of viral strain or subtype. Previous approaches to universal vaccination have required protracted multi-dose
immunizations. Here we evaluate a single dose universal vaccine strategy using recombinant adenoviruses (rAd) expressing
the conserved influenza virus antigens matrix 2 and nucleoprotein.
Methodology/Principal Findings: In BALB/c mice, administration of rAd via the intranasal route was superior to
intramuscular immunization for induction of mucosal responses and for protection against highly virulent H1N1, H3N2, or
H5N1 influenza virus challenge. Mucosally vaccinated mice not only survived, but had little morbidity and reduced lung
virus titers. Protection was observed as early as 2 weeks post-immunization, and lasted at least 10 months, as did antibodies
and lung T cells with activated phenotypes. Virus-specific IgA correlated with but was not essential for protection, as
demonstrated in studies with IgA-deficient animals.
Conclusion/Significance: Mucosal administration of NP and M2-expressing rAd vectors provided rapid and lasting
protection from influenza viruses in a subtype-independent manner. Such vaccines could be used in the interval between
emergence of a new virus strain and availability of strain-matched vaccines against it. This strikingly effective single-dose
vaccination thus represents a candidate off-the-shelf vaccine for emergency use during an influenza pandemic.
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Introduction
Pandemic influenza represents a major threat to global public
health, with the potential for sudden emergence and explosive
transmission of virus strains to which humans have little or no
serologic immunity. Conventional influenza vaccines function by
inducing antibodies against the highly variable surface glycopro-
teins hemagglutinin (HA) and neuraminidase (NA), and currently
take at least 6 months to prepare and distribute once a potential
pandemic strain has been identified [1,2]. This was highlighted by
the 2009 swine origin H1N1 pandemic virus: the newly emergent
virus was identified in April but sufficient vaccine for mass
immunization was not available until October. Meanwhile the
virus was spreading in the community [3,4].
So-called ‘‘universal’’ influenza vaccines providing cross-pro-
tective immunity in a strain- and subtype-independent manner
could mitigate the impact of newly emergent virus strains when
strain-matched vaccines are not yet available [5–7]. Universal
vaccines would provide heterosubtypic immunity directed against
viral components conserved among all influenza A viruses, and
could be stockpiled for use in controlling outbreaks. While
heterosubtypic immunity does not prevent infection, it can reduce
morbidity and mortality and promote accelerated viral clearance
[5,6], resulting in a shortened period of viral shedding and reduced
transmission of virus.
In recent years considerable attention has been paid to the
challenge of generating effective immune responses at mucosal
surfaces. Mucosal surfaces are sites of pathogen entry, replication
and pathology, making immune responses at these locations
critical for effective immunity [8]. Candidate influenza vaccines
delivered intranasally and inducing mucosal immunity include
live-attenuated viruses [9], adjuvanted killed vaccines [10,11], and
recombinant viral vectors. Recombinant adenovirus (rAd) vectors
are potently immunogenic [12,13] and induce effective pathogen-
specific mucosal immunity when delivered intranasally [14–17].
rAd vectors are under investigation in more than 300 human
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[18], including several phase II and III studies (http://www.
clinicaltrials.gov).
We and others have progressively refined DNA and rAd
immunization strategies that induce heterosubtypic protection
against influenza virus, including virulent H5N1 strains [19–22].
In a previous study, we demonstrated a prime-boost regimen that
generated heterosubtypic immunity focused on conserved viral
antigens and was able to protect both mice and ferrets from lethal
influenza virus challenge [21]; others showed that this protection
could be overcome with very high H5N1 challenge doses [23].
Crucially, prime-boost approaches require a protracted multi-dose
immunization regimen, a drawback for use in response to
emerging viruses. Building on this earlier work, we sought to
streamline induction of heterosubtypic protection by harnessing
the power of mucosal immunity.
Here we report a single-dose mucosal vaccination inducing
heterosubtypic immunity using rAd vectors expressing the
conserved viral antigens nucleoprotein (NP) and matrix 2 (M2).
This strategy represents a strong candidate for a subtype-
independent universal vaccine that could be stockpiled and
deployed in the early stages of an influenza pandemic.
Results
Comparison of route of administration and antigen
choice
Initial experiments compared effectiveness of a single intramus-
cular (i.m.) or intranasal (i.n.) immunization with A/NP-, M2-, or
a combination of A/NP+M2-rAd against challenge infection with
a virulent mouse-adapted H1N1 strain (A/FM). A/NP- or M2-
rAd given i.m. failed to protect (defined by survival: see Materials
and Methods) following A/FM challenge (Figure 1). The A/
NP+M2-rAd combination given i.m. did protect, albeit with
significant weight loss. In contrast, the same rAd-immunizations
given i.n. were significantly more effective, with A/NP-rAd
providing 80% survival (P,0.05 vs. i.m.), M2-rAd providing
90% survival (P,0.05 vs. i.m.), and the A/NP+M2-rAd
combination providing complete protection. This enhanced
protection was reflected in reduced weight loss. These results
show that altering the route from parenteral injection to mucosal
administration at an anatomically relevant site dramatically
improves vaccine effectiveness. As A/NP+M2-rAd provided
optimal protection, subsequent experiments focused on this
combination.
Intranasal rAd immunization triggers strong mucosal
immune responses
Anatomically compartmentalized immune responses are ob-
served in DNA prime-rAd boost immunization [21], so we
explored this for single-dose rAd immunization. Mice were
immunized i.m. or i.n. with A/NP+M2-rAd or rAd expressing
influenza B virus nucleoprotein (B/NP-rAd) which serves as a
specificity control to rule out innate immune protection due to the
rAd vector. Antibody, T-cell, and cytokine responses were
analyzed at one and ten months post-immunization.
At one month post-A/NP+M2-rAd immunization, serum IgG
levels against M2e were high and equivalent between mice
vaccinated i.n. and i.m. (Figure 2A), but IgG levels in
bronchoalveolar lavage (BAL) were higher after i.n. than i.m.
immunization. IgA against M2e was detectable only following i.n.
immunization, with levels in BAL considerably higher than in
serum. These differences in the antibody response were main-
tained at 10 months post-immunization (Figure 2B). Similar
results were seen for antibodies against rNP (Figure S1).
Elevated pro-inflammatory cytokine levels in BAL (IFN-c,
mKC, IL-12) were seen after i.n. but not i.m. rAd immunization,
regardless of the transgene, at both one and 10 months post-
immunization (Figure 2C and D). Levels of other cytokines in
BAL (IL-1b, IL-2, IL-4, IL-5, IL-10 and TNF-a) were low at both
one and 10 months and equivalent between groups (data not
shown). Serum cytokine levels were low and similar between
groups at both one and 10 months (data not shown).
T-cell responses against conserved viral epitopes were assessed
by IFN-c ELISPOT analysis of spleen (Figure 2E and F) and
lung cells (Figure 2G and H). At one month post-immunization,
strong responses to the immunodominant H2-K
d restricted NP147–
155 epitope were seen in spleen after i.m. but not i.n. immunization
with A/NP+M2-rAd. The converse was observed in lungs, with
Figure 1. Single-dose i.n. rAd immunization protects from
lethal influenza virus challenge. Groups of ten 12-week old BALB/
cAnNCr mice were immunized with 1610
10 particles of A/NP-rAd or M2-
rAd, or with 1610
10 particles each of A/NP and M2-rAd, via the i.m. or
i.n. routes. 4 weeks after immunization, animals were challenged i.n.
with 10
4 TCID50 (100 LD50) A/FM/1/47-ma (H1N1) and monitored for
survival (A) and weight loss (B).
doi:10.1371/journal.pone.0013162.g001
Ad Universal Influenza Vaccine
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13162Figure 2. Immune responses after single-dose rAd immunization. BALB/cAnNCr mice were immunized with 5610
9 particles each of A/NP-
rAd and M2-rAd, or 1610
10 particles of B/NP-rAd i.n. or i.m., or were unimmunized (naı ¨ve). Analyses were performed at one month (A, C, E, G) or 10
months (B, D, F, H) post-immunization. (A, B) M2e-specific IgG (left panels) and IgA (right panels) responses in serum and BAL were measured by
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following i.n. compared to i.m. immunization. Reponses to MHC-
II restricted epitopes (M2e2–24 and NP55–69) followed a similar
pattern but were of lower magnitude. Responses to rAd epitopes
Hex486–494 and Dbp413–421 were independent of the transgene and
much higher in spleen after i.m. than after i.n. immunization, but
were similar in magnitude in lungs regardless of immunization
route. Similar compartmentalization of the T-cell response was
observed at 10 months post-immunization. Responses to the
dominant NP147–155 epitope in both spleen and lungs were
similar in magnitude to those at 1 month. In contrast, the M2e2-
24-specific response in the spleen was lower than at 1 month but
was considerably greater in the lungs of A/NP+M2-rAd i.n. mice.
The response to rAd epitopes was much lower at 10 months than
at one month regardless of the route of administration or
transgene.
Tetramer staining confirmed that animals immunized with A/
NP+M2-rAd i.n. had more NP147–155-specific CD8
+ T cells
recoverable from lungs than i.m. immunized animals (Figure 3A).
Compared to i.m. rAd immunized mice, a greater proportion of
tetramer positive cells from lungs of i.n. rAd immunized mice
showed an effector memory (CD62L
lo) phenotype, and the
majority were also CD127
lo (Figure 3B). A smaller proportion
of cells with this activated phenotype were seen in the NP147–155-
tetramer negative population, which contains T cells specific to
other epitopes including the rAd vector. More CD8
+ T cells (both
ELISA as described. Bars show mean 6 SEM of 3 mice per group. The dashed line indicates limit of detection. (C, D) Pro-inflammatory cytokine levels
in BAL were measured as described. Bars show mean 6 SEM of 4 mice per group at 1 month or 3 mice per group at 10 months. T-cell responses
in spleen (E, F) and lung (G, H) were measured by IFN-c ELISPOT of triplicate wells after stimulation with NP147–155, Hex486–494, Dbp413–421, M2e2–24,
NP55–69 peptides. Unstimulated cells (no peptide) were used as controls. Bars show mean total IFN-c secreting cell number per organ 6 SEM of 4 mice
per group at month or 3 mice per group at 10 months. Statistically significant differences are indicated as follows: * P,0.05 compared to all other
groups; { P,0.05 compared to i.m. and naı ¨ve groups; { P,0.05 compared to i.n. and naı ¨ve groups; ** P,0.05 compared to B/NP-rAd and naı ¨ve
groups; 1 P,0.05 compared to A/NP+M2-rAd i.n. and naı ¨ve groups; # P,0.05 compared to all other groups except A/NP+M2-rAd i.m.
doi:10.1371/journal.pone.0013162.g002
Figure 3. Lung T cell phenotyping. BALB/cAnNCr mice were immunized with 5610
9 particles each of A/NP-rAd and M2-rAd, or 1610
10 particles
of B/NP-rAd i.n. or i.m., or were unimmunized (naı ¨ve). Lung T cells were isolated and analyzed by flow cytometry. (A) Total number of K
d-NP147–155-
tetramer positive CD8
+ T cells recovered from the lungs of mice, as determined by multicolor flow cytometry. Bars show mean 6 SEM of 3 animals
per group. (B) Phenotypic analysis of lung CD8
+ T cells. Pie charts show relative proportions of central memory (CD62L
hi), effector memory (CD62L
lo,
CD127
hi) and activated effector memory (CD62L
lo, CD127
lo) among tetramer positive (upper pies) and tetramer negative (lower pies) CD8
+ T-cells. (C)
Activation status of lung CD8
+ T cells, as determined by staining for tetramer vs. CD69. Each plot shows one representative mouse per group of 3
mice assessed. Numbers in plots indicate % of CD8
+ T cells per quadrant. * Indicates a statistically significant difference (P,0.05) compared to all
other groups.
doi:10.1371/journal.pone.0013162.g003
Ad Universal Influenza Vaccine
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13162tetramer positive and negative) expressed the early activation
marker CD69 after i.n. than i.m. immunization (Figure 3C),
indicating that not only did i.n. rAd immunization result in greater
virus-specific CD8
+ T-cell responses in the lung, but these cells also
possessed a more activated phenotype than cells induced by i.m.
immunization.
Intranasal rAd immunization provides long-lived
protection from virulent influenza virus challenge
Immunized animals were tested for protection against challenge
with a highly pathogenic H5N1 strain with pandemic potential
(A/VN1203) at both one and 10 months post-immunization. At
one month after immunization, all animals in the A/NP+M2-rAd
i.n. group were protected and had little weight loss (Figure 4). In
contrast, the A/NP+M2-rAd i.m. group suffered significant weight
loss and 30% died by day 11. Control animals died by day 8. Lung
virus titers 3 days post-challenge were significantly lower in mice
immunized with A/NP+M2-rAd by either route than in controls,
with titers significantly lower after A/NP+M2-rAd i.n. than i.m.
immunization. At day 5, only A/NP+M2-rAd i.n. immunized
mice had significantly lower titers than controls. When challenged
10 months after immunization, control animals died with
comparable kinetics to those challenged at 1 month. All A/
NP+M2-rAd i.n. immunized animals were protected with little
weight loss, but A/NP+M2-rAd i.m. immunized animals suffered
more severe weight loss than at 1 month and 37.5% succumbed to
infection (Figure 4D and E). Lung virus titers at both days 3 and
5 post-challenge were significantly lower than controls in mice
immunized with A/NP+M2-rAd via either route. Interestingly,
virus titers in A/NP+M2-rAd immunized mice were lower at 10
months than at one month (Figure 4C and F). Despite these
reduced lung virus titers, the A/NP+M2-rAd i.m. group had worse
outcomes than at one month. The reasons for this are unclear.
Protection was also assessed in immunized animals challenged
with a virulent mouse-adapted H3N2 strain [X-79] (Figure S2).
Complete protection was seen in mice immunized with A/
NP+M2-rAd via either route when challenged with X-79 one
month after vaccination, although significantly greater weight loss
(P,0.05) was observed for i.m. than i.n. immunized animals. Lung
virus titers at day 3 were lower in the A/NP+M2-rAd groups than
in control groups, with titers significantly lower (P,0.05) after i.n.
compared to i.m. immunization. At day 5, lung virus titers were
further reduced and similar between A/NP+M2-rAd i.m. and i.n.
groups. At 10 months post-A/NP+M2-rAd immunization, com-
plete protection with minimal weight loss was maintained in mice
immunized i.n., but was waning in animals immunized i.m. (75%
protection with severe weight loss). This is reflected in day 3 lung
virus titers, which were significantly lower in A/NP+M2-rAd i.n.
mice than in all other groups.
IgA is not required for protection
As virus-specific IgA was detectable after i.n. but not i.m. rAd
immunization, the role of this response in enhanced protection
was examined. BALB/c-IgA
2/2 mice were immunized with A/
NP+M2-rAd i.n. or i.m., or with B/NP-rAd i.n. as a control. M2e-
specific IgG was detectable in serum 2 weeks post-immunization
(Figure 5A) and the IFN-c ELISPOT response in PBMCs
(Figure 5B) was similar to wild-type mice (see Figure S3B).
When challenged with A/FM one month post-immunization all
control animals died, while i.m. immunized animals lost
considerable weight and 50% died (Figure 5C and D). The
i.n. immunized animals lost significantly less weight than i.m.
immunized mice and survived challenge, indicating that while IgA
may play a role following i.n. rAd immunization, it is not required
for protection and is likely not the sole reason for superiority of
mucosal immunization.
Intranasal immunization rapidly induces protection
Universal vaccines could be deployed when strain-matched
vaccines are unavailable, providing interim protection early in a
pandemic. To evaluate this potential, we examined how rapidly
protection develops. Mice were immunized i.n. or i.m., then
challenged with A/FM at various times post-immunization and
monitored for survival and weight loss (Figure 6). Control
animals immunized with B/NP-rAd lost significant weight and
died. Partial protection was observed in A/NP+M2-rAd i.m. mice
challenged one week post-immunization although animals lost
significant weight. This partial protection was lost at 2 and 3 weeks
but began to reappear at 4 weeks and good protection was
observed at 6 months despite significant weight loss. Animals
immunized with A/NP+M2-rAd i.n. showed little protection at
one week but had 90% protection at 2 weeks and complete
protection with little weight loss from 3 weeks out to at least 6
months post-immunization.
Examination of antibody levels in the serum revealed that IgG
specific to M2e was detectable within one week of i.m.
immunization and within 2 weeks for i.n. immunization (Figure
S3A). IgG reached maximal levels by 5 weeks and remained high
for at least 6 months. Serum IgA responses became detectable in
i.n. immunized mice by 2 weeks after immunization for M2e. The
IgA response was absent in the case of i.m. immunization. Again,
development of a virus-specific serum IgA response correlated with
protection for the i.n. rAd immunized groups. However there was
no serum antibody correlate for the partial protection observed in
i.m. immunized mice at one week; although IgG responses against
M2e were observed early after i.m. immunization, they increased
further at weeks 2–5 as protection decreased.
As assessed by IFN-c ELISPOT, virus specific T cell levels in
peripheral blood were modest one week after i.m. rAd immuni-
zation, higher at 2–4 weeks, and then declined to approximately
one third of peak levels at 6 months post-immunization (Figure
S3B). As expected, strong responses were seen against the
immunodominant NP147–155 peptide, with lower responses
directed to NP55–69 and M2e2–24 helper T cell epitopes. Peripheral
blood T-cell responses to NP147–155 following i.n. rAd immuniza-
tion were lower and rose later than after i.m. immunization but
did not decline by 6 months (Figure S3B).
Intranasal rAd immunization confers accelerated
challenge virus clearance
Kinetic studies of lung virus titers were performed to assess rate
of virus clearance after A/FM challenge. Maximal titers were seen
2 days post-challenge in all groups (Figure 7) with B/NP-rAd
immunized mice retaining high titers through day 7. A/NP+M2-
rAd i.m. immunized mice had peak virus titers similar to those of
B/NP-rAd mice but exhibited a steady decrease in titer from day 3
onward, with virus clearance complete by day 10. Mice
immunized with A/NP+M2-rAd i.n. showed significantly lower
titers (P,0.001) as early as day 2 post-challenge and cleared virus
more rapidly than the other groups, with clearance complete by
day 7.
Discussion
The recent emergence of an unanticipated pandemic virus has
highlighted the need for influenza vaccines providing broad
coverage across multiple strains and subtypes. This study
demonstrates that a single dose of rAd vaccines expressing two
Ad Universal Influenza Vaccine
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from virulent influenza virus challenges with multiple widely
divergent subtypes. Protection is greatly enhanced by i.n.
administration, develops by 2 weeks post-immunization, and
persists for at least 10 months. Intranasal rAd vaccination
decreased lung virus titers and accelerated challenge virus
clearance relative to i.m. vaccination. This reduction in virus
titers corresponded to greatly reduced morbidity, as shown by
weight loss, compared to controls and i.m. immunized animals.
Antibody and T-cell responses against both NP and M2 were
seen. Previous work suggests that dominant protective mechanisms
are likely M2e-specific antibodies that limit viral spread [24] and
Figure 4. Morbidity and mortality after H5N1 challenge following single-dose rAd immunization. Groups of 10 (at one month) or 8 (at
10 months) BALB/cAnNCr mice were challenged with 10
2.84 EID50 (,10 LD50) of A/VN1203 one month (A, B, C) or 10 months (D, E, F) after
immunization. (A, D) Survival after challenge. (B, E) Weight loss after challenge. When challenged one month post-boosting, statistically significant
differences in weight loss (P,0.05) were observed between A/NP+M2-rAd i.n. and all other groups at days 4–12. When challenged at 10 months,
weight loss in A/NP+M2-rAd i.n. immunized mice was significantly (P,0.05) different from all other groups from days 4–16. (C, F) Virus titers in the
lungs at days 3 and 5 after challenge as determined by plaque assay. Bars show log10 geometric mean titer 6 SEM of 4 mice per group. The dashed
line shows limit of detection. * indicates a statistically significant difference (P,0.05) compared to all other groups at the same time point; ** indicates
a significant difference from B/NP-rAd and naı ¨ve groups.
doi:10.1371/journal.pone.0013162.g004
Figure 5. IgA is not required for protection after i.n. rAd immunization. Groups of 6 IgA
2/2-BALB/c mice were immunized with 5610
9
particles each of A/NP-rAd and M2-rAd i.n. or i.m., or 1610
10 particles of B/NP-rAd i.n. (A) IgG responses against M2e were measured by ELISA using
serum obtained 2 weeks after immunization. The dashed line indicates limit of detection. (B) Antigen-specific T-cell responses at 3 weeks post-
immunization were determined in peripheral blood pooled from these animals by IFN-c ELISPOT using NP147–155,N P 55–69 or M2e2-24 peptides as
stimulus. Unstimulated cells (no peptide) were used as a control. Bars show mean 6 SEM of triplicate wells for each group per stimulus. At one month
post-immunization, animals were challenged with 10
4 TCID50 (100 LD50) of A/FM and monitored for survival (C) and weight loss (D). Error bars in
weight loss graph indicate mean 6 SEM. Statistically significant differences in weight loss (P,0.05) were observed between A/NP+M2-rAd i.n. and i.m.
at days 2–15, between A/NP+M2-rAd i.n. and B/NP-rAd at days 3–13, and between A/NP+M2-rAd i.n. and B/NP-rAd at days 2, 3, 9 and 13.
doi:10.1371/journal.pone.0013162.g005
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13162Figure 6. Kinetics of protection after single-dose rAd immunization. BALB/cAnNCr mice were immunized with 5610
9 particles each of A/NP-
rAd and M2-rAd, or 1610
10 particles of B/NP-rAd i.n. or i.m. and challenged with 10
4 TCID50 (,100 LD50) of A/FM at 1, 2, 3, or 4 weeks or 6 months
later. Left panels show survival and right panels show weight loss after challenge. Groups consisted of 10 mice per immunization per challenge time.
Error bars in weight loss graphs indicate mean 6 SEM. Statistically significant (P,0.05) differences in survival were as follows: A/NP+M2-rAd i.n. was
significantly different from A/NP+M2-rAd i.m. at weeks 2, 3, and 4, and from B/NP-rAd i.n. or i.m. at all times; A/NP+M2-rAd i.m. was significantly
different from B/NP-rAd i.m. at 2 weeks and 6 months, but not different from B/NP-rAd i.n. at any time. In terms of weight loss, no statistically
Ad Universal Influenza Vaccine
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specific CD8
+ T cells eliminating infected cells by cytolysis [26].
M2e and NP-specific helper T cells probably make a lesser
contribution as direct anti-viral effectors. A role for NP-specific
antibody has also been proposed [27], but the significance of this
in protection is debated. As with prime-boost studies [20,21], the
A/NP+M2 rAd vector combination was superior to either
component alone in providing protection, which may be due to
induction of complementary effector mechanisms including virus-
specific IgA and T cells in the respiratory tract.
Targeting multiple viral antigens, in this case NP and M2,
clearly has advantages over using a single antigen. Immunization
with either M2-rAd or A/NP-rAd alone confers less protection
than using a mixture of these two rAd vectors (Figure 1). The A/
NP+M2-rAd combination also has potential advantages in
preventing emergence of viral escape mutants, which have been
reported for NP [28,29] and M2 [30]. However, even under
selective pressure from monoclonal antibodies, very few escape
mutant sequences were observed for M2e [30] suggesting that this
region is biologically constrained. Combination vaccines also
reduce the possibility that individuals with certain HLA types may
be overall non-responders to the vaccine. The latter is a potential
problem with M2 due to the small size of this protein (97 amino
acids) and the limited number of potential epitopes it may contain,
but less of a concern with the larger NP (498 amino acids) within
which multiple epitopes for numerous MHC-I and –II alleles have
been identified [31,32]. It is possible that incorporation of
additional antigens (such as M1 or PB1) into heterosubtypic
vaccines may further broaden and enhance the response.
HA-expressing rAd influenza vaccines intended to induce
strain-matched neutralizing antibodies have been studied in mice
[33,34], chickens [35], and humans [36], but would require
regular reformulation to accommodate antigenic variation in HA.
Recent studies show that monoclonal antibodies against conserved
epitopes in the HA stem region can neutralize viruses of several
subtypes [37–39]. However, such antibodies do not react with all
HA subtypes, so multiple such immunogens would be needed to
cover all subtypes. NP-expressing rAd5 and chimp rAd vectors
given i.m. provided partial protection from both H1N1 and H5N1
challenges in mice [40], but required a higher vaccine dose than
reported here. Our findings demonstrate that a single dose of the
A/NP+M2-rAd combination given i.n. provided complete pro-
tection against highly virulent H1N1, H3N2, and H5N1 influenza
virus challenges.
Compared to the DNA prime-rAd boost approach previously
reported [21], the single-dose rAd strategy reported here has the
advantage of a streamlined vaccination protocol. Significantly, it
obviates the requirement for multiple vaccine doses used in prime-
boost regimens (3 doses of DNA given at 2 week intervals by i.m.
injection, followed by rAd given i.m. or i.n. one month later is
typical). We have previously demonstrated that for NP-based
immunization, DNA priming enhances protection over that of i.m.
rAd alone [41]. However, results reported here suggest that
priming is less critical when rAd is given intranasally.
The public health applications of prime-boost and single-dose
rAd vaccination are quite different. DNA priming could be
administered during routine health care to establish basal
immunity. It would offer partial protection in the event of an
unexpected outbreak or drift, as well as priming for enhanced
responses to rAd or other viral boosts. The DNA vaccines can be
given repeatedly without concern about anti-vector immunity. In
contrast, the single dose rAd vaccination could be used on an
urgent basis early in a pandemic or unexpected outbreak.
Single-dose i.n. rAd protected within 2 weeks, with maximal
protection by 3 weeks, which compares favorably with strain-
matched vaccines. Immunity induced by single-dose rAd is also
long-lived, with complete protection observed for at least 10
months after i.n. immunization. Although i.m. rAd provided some
protection, this did not prevent weight loss and was waning at 10
months. Durable protection is important for vaccines designed to
cover the gap between emergence of a new strain and the
availability of matched vaccines.
Concern has been raised about the possibility of adenovirus
vectors accessing the central nervous system. Although transgene
expression in the olfactory bulb occurs after i.n. administration of
rAd vectors to mice, this is transient, low level, and not associated
with inflammation [42,43]. Another potential limitation of rAd
vaccines is host immunity to the vector which may interfere with
vaccination [12]. This is a particular concern for Ad5-based
Figure 7. Kinetics of virus clearance following H1N1 challenge.
BALB/cAnNCr mice were immunized with 5610
9 particles each of A/NP-
rAd and M2-rAd, or 1610
10 particles of B/NP-rAd i.n. or i.m. and
challenged with 10
4 TCID50 (,100 LD50) of A/FM one month later. Lung
virus titers were measured by TCID50 at the indicated time points, and
are expressed as geometric mean titer 6 SEM of 3 mice per group per
time point, except for day 7 in the B/NP-rAd i.m. group and day 10 in
the B/NP-rAd i.n. group where only 1 mouse remained alive (indicated
by {). The dashed line shows limit of detection. * indicates a statistically
significant difference (P,0.001) compared to all other groups at the
same time point.
doi:10.1371/journal.pone.0013162.g007
significant differences were seen between groups at week 1. At week 2 A/NP+M2-rAd i.n. differed (P,0.05) from all other groups on days 2–7, and
also from B/NP-rAd i.n. on day 1; A/NP+M2-rAd i.m. was significantly different from B/NP-rAd i.n. on days 2–3 and from B/NP-rAd i.m. on day 1. At
week 3 A/NP+M2-rAd differed from all other groups on days 2–8; B/NP-rAd i.n. differed from all other groups on day 3. At week 4 A/NP+M2-rAd i.n.
was significantly different from all other groups on days 2–15; A/NP+M2-rAd i.m. differed from B/NP-rAd i.m. on day 11. At 6 months A/NP+M2-rAd i.n.
was significantly different from all other groups on days 2–10, and from A/NP+M2-rAd i.m. on days 11–15.
doi:10.1371/journal.pone.0013162.g006
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antibody [44]. While experimental animals mount strong immune
responses against rAd vectors, this is not always the case in
humans. In gene therapy trials some individuals do not make
neutralizing antibody responses against rAd given i.n., even after
repeated administrations [45]. Other reports suggest that rAd
immunization may induce de novo T-cell responses against the
transgene despite pre-existing immunity, albeit lower levels than in
seronegative individuals [46]. To circumvent immunity, vectors
based on rare adenovirus serotypes [47], non-human primate
adenoviruses [48], or chimeric viruses [49] have been suggested in
place of current Ad5 vectors.
The rAd doses used here are broadly similar to those used in
other vaccine studies. It may be possible to use lower rAd doses.
Preliminary results using A/NP-rAd given i.n. suggest that similar
levels of protection are achieved with a 10-fold lower rAd dose
(Figure S4). Studies to assess minimum protective doses for the
A/NP+M2-rAd combination are ongoing. An effective rAd
vaccine dose for humans would have to be addressed in future
clinical trials, and may not require a dose proportionate to body
weight. Further vector optimization (for example by encoding both
NP and M2 on a bicistronic vector) may be possible, and could
allow vaccine dose to be reduced still further. It should be noted
that since rAd-based vaccines targeting conserved antigens would
not need to be changed frequently, vaccine manufacture could
occur on an ongoing basis to produce a stockpile, rather than on a
seasonal basis as is the case for current influenza vaccines.
Immune correlates of protection are needed for new vaccine
types. IgA is not required for protection, but may play a role in
protection when present, and could provide a useful correlate.
Serum IgG responses do not correlate with protection. They are
similar between i.n. and i.m. rAd immunizations which differ in
protection (Figure 2A and B; Figure S1), and develop earlier
after i.m. than i.n. rAd, strengthening at 2 weeks as protection
decreases (Figure S3A). Mucosal IgG appears more promising, as
i.n. rAd immunization induced higher BAL IgG responses than
i.m. rAd. Interestingly, this indicates that i.n. rAd immunization
likely induces IgG-secreting cells resident within the respiratory
tract; if antibody reached the BAL by transudation from serum
(where IgG levels are similar between i.n. and i.m. immunized
mice), then BAL IgG levels would be equivalent regardless of
immunization route.
Ideally, correlates of protection should be feasible to assess in
humans with non-invasive sampling methods. Anatomical com-
partmentalization of cellular immune populations after i.n.
immunization (ref. 21 and this study) complicates the matter.
Cellular correlates can be identified, for example IFN-c secreting
virus-specific T cells in the lungs, but cannot be directly measured
in humans. However, the frequency of IFN-c secreting cells in
blood increases between 1 and 6 months after i.n. immunization
(Figure S3B), suggesting equilibration between lung and blood T
cell pools over time. If the relevant lung T cells possess a distinctive
phenotype of memory, homing or activation markers, perhaps low
numbers of comparable cells could be detected in the circulation.
Our studies using a non-replicating viral vector rather than
productive infection are in agreement with reports that virus-
specific T cells resident in the lungs after clearance of viral
infection exhibit an activated phenotype in both mice [50,51] and
humans [52]. While the classic paradigm is that during recall
responses memory T cells activated in draining lymph nodes
recirculate back to the site of infection to clear pathogen, T cells
already present in tissue and re-activated locally may be able to
mediate immediate effector function to control virus [5]. This
agrees with our observation that virus titers were significantly
reduced from 2 days post-challenge, with a trend for lower titers at
day 1, in i.n. but not i.m. immunized animals.
Detection of elevated cytokine levels (IFN-c,m K C ,I L - 1 2 )i n
BAL at both one and 10 months after i.n. rAd vaccination
(Figure 2C and D) is surprising. This was transgene-
independent, and thus due to the rAd vector. mKC (CXCL1)
is a powerful neutrophil chemoattractant and functional homolog
of human IL-8/CXCL8 [53,54]. IFN-c is immunostimulatory
and secreted by various cells including activated T cells and
macrophages [55]. The elevated IFN-c levels in BAL after i.n.
rAd immunization could result from continued IL-12 secretion.
IL-12 promotes differentiation of CD4
+ T cells towards a Th1
phenotype [56] and maintains CD4
+ IFN-c
+ T cell effector
function [57]. Continued IL-12 expression in BAL after i.n. rAd
immunization may maintain CD4
+ T cell activation, which could
sustain the strong virus-specific CD8
+ T-cell responses observed
in the lung.
We have not yet identified the cellular source of the cytokines
seen in BAL, but rAd can infect immature dendritic cells (DC)
from both mice and humans, causing them to mature and secrete
IL-12 [58,59]. This occurs independently of transgene expression
[58] via a TLR9/MyD88 dependent pathway in vitro [60]. Earlier
studies demonstrated that exposure to an aerosolized antigen
induced an activated CD11c
+ CD11b
+ DC subset in BAL that
retained antigen presenting function for several weeks after antigen
exposure [61].
Other studies have been interpreted as showing persistence of
influenza virus antigen after infection, and have suggested that this
maintains the activation of virus-specific T cells generated in
response to infection [51,62–64]. In contrast to the situation with
natural influenza virus infection, previous studies have demon-
strated persistence of both vector genome and antigen expression
for at least a year following i.m. rAd immunization of mice [65].
This sustained antigen expression appears important for support-
ing the activated phenotype of transgene-specific T cells following
rAd immunization [65,66], although maintenance of memory T
cell populations eventually becomes antigen-independent [66].
Differences in expression pattern likely explain the dichotomy
between the T-cell responses against the transgenes (NP and M2
which are driven by a constitutively active CMV promoter) which
were sustained over the duration of the study and responses
against the rAd vector (the E1, E3 deleted vector backbone driving
only minimal and transient expression of Hexon and DNA-
binding protein) which decline substantially over this time.
Ultimately, the combination of prolonged low-level antigen
presentation and Th1 cytokine production may be optimal for
maintaining protective mucosal immune responses.
With their ability to induce potent innate and adaptive immune
responses and to deliver antigen to intracellular processing and
presentation pathways, rAd vectors may be particularly well suited
for vaccination against viruses and other intracellular pathogens.
Here we demonstrate their potential as an emergency, fast-acting
vaccine inducing long-lasting protective immunity in the respira-
tory tract. Heterosubtypic rAd vaccines could be stockpiled in
advance since regular reformulation would be unnecessary, and
could be delivered by nasal spray, facilitating widespread
administration by limited healthcare personnel. During a large
scale virus outbreak or pandemic, reducing disease severity by
vaccination, even while allowing mild infection, could greatly
reduce the burden on healthcare facilities. Conserved antigen
vaccines do not provide the type of sterilizing immunity mediated
by HA-specific neutralizing antibody, but would permit only a
mild, transient natural influenza virus infection. This transient
infection would further boost heterosubtypic immunity and induce
Ad Universal Influenza Vaccine
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the community, preventing re-infection.
Materials and Methods
Ethics statement
All animal protocols and procedures were approved by
Institutional Animal Care and Use Committees at the Center
for Biologics Evaluation and Research (CBER; Protocol #1991-
06) and/or the Centers for Disease Control and Prevention (CDC;
Protocol #1619) in animal facilities accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care
International. All experiments were performed according to
institutional guidelines.
rAd vaccines
Recombinant adenovirus vectors (Ad5-DE1DE3) expressing A/
NP, B/NP or consensus M2 have been described previously
[22,41]. Briefly, Pac I-linearized A/NP- or B/NP-containing
shuttle vectors were recombined with a cosmid containing Ad5
genomic DNA using Cre-recombinase. M2-rAd was constructed
using the ViraPower Adenoviral Expression System (Invitrogen,
Carlsbad, CA) by subcloning the M2-consensus sequence into the
pAd/CMV/V5-DEST Gateway vector using LR Clonase. In each
case, recombinants were transfected into 293 cells for recovery of
rAd vectors. High titer rAd stocks were prepared by ViraQuest
Inc. (North Liberty, IA) and stored at 280uC in PBS with 3%
sucrose. Viral particle concentration was determined by absor-
bance at 260 nm. All rAd stocks were confirmed negative for
replication-competent adenovirus by passage on non-permissive
cells.
Influenza viruses
The highly virulent, mouse-adapted virus A/FM/1/47-ma
(H1N1) [A/FM] [67] originally provided by Earl Brown
(University of Ottawa, Canada), the mouse-adapted A/Philip-
pines/2/82 X A/PR/8/34 (H3N2) reassortant [X-79] [68], and
the systemically replicating avian strain A/Vietnam/1203/2004
(H5N1) [A/VN1203] [69] have been described previously. Virus
stocks were prepared as previously described [20]. Experiments
involving H5N1 virus were conducted under enhanced BSL-3
containment at CDC; all other experiments were conducted under
BSL-2 conditions at CBER.
Experimental animals, immunization, and challenge
infection
Female BALB/cAnNCr mice aged 8–12 weeks purchased from
the National Cancer Institute, Frederick, MD were used for all
experiments, except where indicated. IgA
2/2 mice were originally
obtained by MTA from Baylor University [70] and backcrossed
onto the BALB/c background in our colony using marker-assisted
accelerated backcrossing (MAX-BAX) technology from Charles
River Laboratories (Wilmington, MA). BALB/c-IgA
2/2 mice
were bred in the CBER colony. Intramuscular injection of rAd
vaccine used a 100 ml volume split evenly between each rear
quadriceps muscle; intranasal immunization used a 50 ml volume
delivered under isoflurane anesthesia. H1N1 and H3N2 challenge
infections were performed under isoflurane anesthesia; 2,2,2-
tribromoethanol in tert-amyl alcohol (Avertin; Aldrich Chemical
Co., Milwaukee, WI) given i.p. was used as anesthetic for H5N1
challenge. Following challenge infection, animals were monitored
for weight loss and survival. In this paper the term ‘‘protection’’ is
defined as survival following challenge infection, and does not
imply complete absence of virus replication.
Mucosal sampling
Mice were euthanized with ketamine/xylazine, and broncho-
alveolar lavage (BAL) and lung cells were obtained as described
previously [21].
Peptides and proteins
The following peptides were synthesized by the CBER core
facility: NP147–155 (TYQRTRALV), NP55–69 (RLIQNSL-
TIERMVLS), and M2e2–24 consensus sequence (SLLTEVET-
PIRNEWGCRCNDSSD) corresponding to the surface exposed
M2 ectodomain region (M2e). The MHC-I restricted adenovirus 5
hexon (Hex486–494: KYSPSNVKI) and DNA-binding protein
(Dbp419–427: FALSNAEDL) peptides [71] were synthesized by
GenScript (Piscataway, NJ). Recombinant nucleoprotein (rNP)
from strain A/PR/8/34 (H1N1) was purchased from Imgenex
(San Diego, CA).
T cell ELISPOT
Interferon (IFN)- c ELISPOT was performed as previously
described [22] on lung and spleen cells by stimulation with
indicated peptides.
Flow cytometry
Lung and spleen T cell phenotypes were assessed by surface
staining with CD3-eFluor450, CD8-APC-eFluor780, CD62L-PE-
Cy7, CD69-PE, CD127-PerCP-Cy5.5 (all from eBiosciences, San
Diego, CA), NP147–155-H2-K
d Tetramer-APC (NIH Tetramer
core facility, Atlanta, GA), and Live/Dead fixable viability stain
for 488 nm excitation (Invitrogen, Carlsbad, CA). 50,000 events
were acquired on a BD-FACS Canto II and data analyzed with
FlowJo (TreeStar, Ashland, OR) software. Thresholds of positivity
were identified using fluorescence minus one controls for each
color on cells from each sample group.
Cytokine Analysis
Cytokine levels in BAL were assessed using the Meso Scale
Discovery mouse Th1/Th2 9-plex ultra-sensitive kit (MSD,
Gaithersburg, MD), according to manufacturer’s instructions.
This kit allows simultaneous quantitation of murine IL-1b, IL-2,
IL-4, IL-5, IL-10, total IL-12, IFN-c, mKC, and TNF-a.
Antibody analysis
Antibody levels in serum and BAL were assessed by ELISA, as
described previously [20,21]. Data are expressed as endpoint
titers, defined as the highest dilution of sample giving an OD
405 nm reading greater than 3 SD above the mean of the naı ¨ve
samples.
Virus titration
Virus titers in tissues were determined by plaque assay (for A/
VN1203) or TCID50 (for A/FM) as described previously [21,72].
Statistical analysis
SigmaStat v 3.5 (Systat Software, Point Richmond, CA) was
used for all statistical analyses. Body weight and virus titers
analyses used one way ANOVA, followed by pairwise multiple
comparisons via the Holm-Sidak method. Survival analysis was
performed by the Log-Rank method.
Supporting Information
Figure S1 Serum and BAL antibody responses to nucleoprotein.
Mice were immunized with 5610
9 particles each of A/NP-rAd
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10 particles of B/NP-rAd i.n. or i.m., or were
unimmunized (naı ¨ve). rNP-specific IgG (left panels) and IgA (right
panels) responses in serum and BAL were measured by ELISA as
described one month (A) and 10 months (B) after immunization.
Bars show mean 6 SEM of 3 mice per group. The dashed line
indicates limit of detection. Statistically significant differences are
indicated as follows: * P,0.05 compared to all other groups;
** P,0.05 compared to B/NP-rAd and naı ¨ve groups.
Found at: doi:10.1371/journal.pone.0013162.s001 (0.56 MB
TIF)
Figure S2 Morbidity and mortality after H3N2 challenge
following single dose rAd immunization. Groups of 10 (at one
month) or 8 (at 10 months) mice were challenged with 5610
4
TCID50 (,100 LD50) of X-79 one month (A, B and C) or 10
months (D, E and F) after immunization. (A, D) Survival after
challenge. (B, E) Weight loss after challenge. When challenged one
month post boosting statistically significant differences in weight
loss (P,0.05) were observed between A/NP+M2-rAd i.n. and i.m.
groups at days 1–7, between A/NP+M2-rAd i.n. and B/NP-rAd
or naı ¨ve groups at days 1–15, and between A/NP+M2-rAd and
B/NP or naive groups at days 5–15. When challenged at 10
months weight loss in A/NP+M2-rAd i.n. immunized mice was
significantly (P,0.05) different from all other groups from days 3–
11 and 13–15. (C, F) Virus titers in the lungs at days 3 and 5 after
challenge, as determined by TCID50. Bars show log10 geometric
mean titer 6 SEM of 4 mice per group, or 3 mice per group at 10
months. The dashed line shows limit of detection. * indicates a
statistically significant difference (P,0.05) compared to all other
groups at the same time point; ** indicates a significant difference
from B/NP-rAd and naı ¨ve groups; {dagger} indicates a significant
difference from B/NP-rAd groups. Note that day 5 titers were not
assessed at 10 months.
Found at: doi:10.1371/journal.pone.0013162.s002 (0.68 MB TIF)
Figure S3 Kinetics of the immune response after single-dose rAd
immunization. Mice were immunized with 5610
9 particles each of
A/NP-rAd and M2-rAd, or 1610
10 particles of B/NP-rAd i.n. or
i.m. (A) M2e-specific IgG (left panels) and IgA (right panels)
responses in serum collected 1, 2, 3, or 5 weeks or 6 months post-
immunization were measured by ELISA. Bars show endpoint titer
of serum pooled from 10 mice per group. The dashed line
indicates limit of detection. For measurement of T-cell responses
by IFN-c ELISPOT (B), peripheral blood from 10 mice per group
was collected and pooled at 1, 2, 3, or 4 weeks or 6 months post-
immunization, as indicated. T-cell responses were determined
using NP147–155,N P 55–69 or M2e2–24 peptides as stimulus.
Unstimulated cells (no peptide) were used as a control. Bars show
mean 6 SEM of triplicate wells for each group per stimulus. For
the A/NP+M2-rAd i.m. group at 2 weeks, specific T-cell responses
could not be determined due to high background observed in all
test wells. This is indicated by HB in (B). This high background
was not seen in a repeat experiment.
Found at: doi:10.1371/journal.pone.0013162.s003 (0.63 MB TIF)
Figure S4 Dose titration of i.n. A/NP-rAd immunization.
Groups of 12-week old BALB/cAnNCr mice were immunized
i.n. with 1610
10 (10 mice), 1610
9 (5 mice), or 1610
8 (5 mice)
particles of A/NP-rAd. 4 weeks after immunization, animals were
challenged i.n. with 10
4 TCID50 (100 LD50) A/FM/1/47-ma
(H1N1) and monitored for survival (A) and weight loss (B).
Found at: doi:10.1371/journal.pone.0013162.s004 (0.57 MB TIF)
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